Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia.
Klossowski S, Miao H, Kempinska K, Wu T, Purohit T, Kim E, Linhares BM, Chen D, Jih G, Perkey E, Huang H, He M, Wen B, Wang Y, Yu K, Lee SC, Danet-Desnoyers G, Trotman W, Kandarpa M, Cotton A, Abdel-Wahab O, Lei H, Dou Y, Guzman M, Peterson L, Gruber T, Choi S, Sun D, Ren P, Li LS, Liu Y, Burrows F, Maillard I, Cierpicki T, Grembecka J. Klossowski S, et al. Among authors: linhares bm. J Clin Invest. 2020 Feb 3;130(2):981-997. doi: 10.1172/JCI129126. J Clin Invest. 2020. PMID: 31855575 Free PMC article.
Complexity of Blocking Bivalent Protein-Protein Interactions: Development of a Highly Potent Inhibitor of the Menin-Mixed-Lineage Leukemia Interaction.
Borkin D, Klossowski S, Pollock J, Miao H, Linhares BM, Kempinska K, Jin Z, Purohit T, Wen B, He M, Sun D, Cierpicki T, Grembecka J. Borkin D, et al. Among authors: linhares bm. J Med Chem. 2018 Jun 14;61(11):4832-4850. doi: 10.1021/acs.jmedchem.8b00071. Epub 2018 May 23. J Med Chem. 2018. PMID: 29738674 Free PMC article.
Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design.
Cheng H, Linhares BM, Yu W, Cardenas MG, Ai Y, Jiang W, Winkler A, Cohen S, Melnick A, MacKerell A Jr, Cierpicki T, Xue F. Cheng H, et al. Among authors: linhares bm. J Med Chem. 2018 Sep 13;61(17):7573-7588. doi: 10.1021/acs.jmedchem.8b00040. Epub 2018 Jul 17. J Med Chem. 2018. PMID: 29969259 Free PMC article.
GAS41 Recognizes Diacetylated Histone H3 through a Bivalent Binding Mode.
Cho HJ, Li H, Linhares BM, Kim E, Ndoj J, Miao H, Grembecka J, Cierpicki T. Cho HJ, et al. Among authors: linhares bm. ACS Chem Biol. 2018 Sep 21;13(9):2739-2746. doi: 10.1021/acschembio.8b00674. Epub 2018 Aug 17. ACS Chem Biol. 2018. PMID: 30071723 Free PMC article.
Development of potent dimeric inhibitors of GAS41 YEATS domain.
Listunov D, Linhares BM, Kim E, Winkler A, Simes ML, Weaver S, Cho HJ, Rizo A, Zolov S, Keshamouni VG, Grembecka J, Cierpicki T. Listunov D, et al. Among authors: linhares bm. Cell Chem Biol. 2021 Dec 16;28(12):1716-1727.e6. doi: 10.1016/j.chembiol.2021.06.010. Epub 2021 Jul 21. Cell Chem Biol. 2021. PMID: 34289376 Free PMC article.
Increased slow dynamics defines ligandability of BTB domains.
Kharchenko V, Linhares BM, Borregard M, Czaban I, Grembecka J, Jaremko M, Cierpicki T, Jaremko Ł. Kharchenko V, et al. Among authors: linhares bm. Nat Commun. 2022 Nov 16;13(1):6989. doi: 10.1038/s41467-022-34599-6. Nat Commun. 2022. PMID: 36384931 Free PMC article.
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.
Wang ES, Issa GC, Erba HP, Altman JK, Montesinos P, DeBotton S, Walter RB, Pettit K, Savona MR, Shah MV, Kremyanskaya M, Baer MR, Foran JM, Schiller G, Adès L, Heiblig M, Berthon C, Peterlin P, Rodríguez-Arbolí E, Salamero O, Patnaik MM, Papayannidis C, Grembecka J, Cierpicki T, Clegg B, Ray J, Linhares BM, Nie K, Mitra A, Ahsan JM, Tabachri M, Soifer HS, Corum D, Leoni M, Dale S, Fathi AT. Wang ES, et al. Among authors: linhares bm. Lancet Oncol. 2024 Oct;25(10):1310-1324. doi: 10.1016/S1470-2045(24)00386-3. Lancet Oncol. 2024. PMID: 39362248 Clinical Trial.
14 results